Seronegative antibody‐mediated neurology after immune checkpoint inhibitors
Checkpoint inhibitor medications have revolutionized oncology practice, but frequently induce immune‐related adverse events. During autoimmune neurology practice over 20 months, we prospectively identified four patients with likely antibody‐mediated neurological diseases after checkpoint inhibitors:...
主要な著者: | , , , , , , , , , , , , , |
---|---|
フォーマット: | Journal article |
出版事項: |
Wiley
2018
|